Renal protection in diabetes: lessons from ONTARGET

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hypertension is a primary risk factor for renal disease.
• Co-existing hypertension and chronic kidney disease, common in diabetes, elevate cardiovascular disease risk.
• Albuminuria signifies renal damage and predicts cardiovascular events.

Purpose of the Study:

• To evaluate the renoprotective effects of angiotensin II receptor blockers (ARBs), specifically telmisartan.
• To assess telmisartan's impact on blood pressure, renal function, and albuminuria progression.
• To compare telmisartan's renoprotective effects beyond blood pressure control.

Main Methods:

• Review of clinical studies on telmisartan in patients with hypertension and renal disease, including those with diabetes mellitus.
• Analysis of data on blood pressure control, albuminuria, glomerular filtration rate, and proteinuria.
• Examination of the role of the renin-angiotensin system (RAS) in renal and cardiovascular disease.

Main Results:

• Telmisartan provides 24-hour blood pressure control and demonstrates renoprotective effects in diabetic nephropathy.
• Clinical studies show telmisartan improves renal endothelial function, prevents albuminuria progression, and slows decline in glomerular filtration rate.
• Telmisartan's renoprotective effects extend beyond diabetic nephropathy, as shown in the ONTARGET trial for high-risk patients.

Conclusions:

• Rigorous blood pressure control is crucial for patients with hypertension and chronic kidney disease.
• Agents targeting the renin-angiotensin system, like telmisartan, offer significant renoprotection.
• Telmisartan's benefits in slowing kidney disease progression are evident in both diabetic and non-diabetic individuals at high cardiovascular risk.